SEC v. Kin-Hung Peony Yu

Kin-Hung Peony Yu allegedly made false and misleading statements about the cardiovascular safety of FibroGen’s then-primary drug candidate, roxadustat. According to the SEC’s complaint, Dr. Yu misled investors with claims that the results of key studies established that roxadustat was superior in cardiovascular safety to the primary existing treatment. Dr. Yu allegedly failed to disclose to investors that she had reverse engineered the results.

Summary generated from official Securities and Exchange Commission press release